Consider the Use of Factor viia to Treat Medical Bleeding in a Surgical or Trauma Patient
Suneel Khetarpal MD
Andrew J. Kerwin MD
The primary initial goal in the care of the trauma patient has always been control of hemorrhage. Under most circumstances this can be achieved by surgical control or more recently by other adjuncts such as angiography. However, in the massively injured patient a second form of bleeding commonly referred to as nonsurgical bleeding can pose a significant threat to life. The etiology of this nonsurgical bleeding is multifactorial; it results from a significant decrease in hemostatic components (platelets, fibrinogen, and coagulation factors) as well as unfavorable conditions for enzyme kinetics such as acidosis, hypothermia, and hypocalcemia. The end result is that the patient develops diffuse bleeding that cannot be controlled by surgical methods.
Watch Out For
The primary treatment of nonsurgical bleeding is prevention. Early recognition of predisposing factors such as hypothermia, correction of acidosis by improved resuscitation, and replacement of blood and blood products can help protect against the development of coagulopathy in trauma patients. However, coagulopathic bleeding may still be present in as much as 35% of severely traumatized individuals and its incidence increases with the severity of trauma. The treatment of such individuals has traditionally been supportive. Recently, there have been an increasing number of cases supporting the use of recombinant factor VII in the therapy of this uncontrolled nonsurgical bleeding.